Wird geladen...

Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

BACKGROUND. In the phase III ALSYMPCA trial, metastatic castration‐resistant prostate cancer (mCRPC) patients had few prior life‐prolonging therapies. Following ALSYMPCA, which demonstrated radium‐223 survival benefit, and before radium‐223 U.S. commercial availability, an expanded access program (E...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Sartor, Oliver, Vogelzang, Nicholas J., Sweeney, Christopher, Fernandez, Daniel C., Almeida, Fabio, Iagaru, Andrei, Brown, Alan, Smith, Matthew R., Agrawal, Manish, Dicker, Adam P., Garcia, Jorge A., Lutzky, Jose, Wong, Yu‐Ning, Petrenciuc, Oana, Gratt, Jeremy, Shore, Neal D., Morris, Michael J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2017
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813754/
https://ncbi.nlm.nih.gov/pubmed/29183960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0413
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!